Pub Date : 2023-01-01DOI: 10.4103/ds.ds-d-22-00154
S. Shao, Liang-Tseng Kuo, Yen-Ta Huang, P. Lai, Ching-Chi Chi
The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework offers a structured approach to assess the certainty of evidence (CoE) in systematic reviews (SRs). The CoE for each outcome falls into one of the four categories: very low, low, moderate, or high. The judgment of CoE is based on five downgrading factors (including the risk of bias, indirectness, inconsistency, imprecision, and publication bias) and three upgrading factors (including large effect size, dose-response relationship, and opposing plausible residual bias and confounding). To improve the transparency of SRs, authors should indicate how they grade the CoE for each outcome and provide a rationale for downgrading or upgrading the CoE.
{"title":"Using Grading of Recommendations Assessment, Development, and Evaluation (GRADE) to rate the certainty of evidence of study outcomes from systematic reviews: A quick tutorial","authors":"S. Shao, Liang-Tseng Kuo, Yen-Ta Huang, P. Lai, Ching-Chi Chi","doi":"10.4103/ds.ds-d-22-00154","DOIUrl":"https://doi.org/10.4103/ds.ds-d-22-00154","url":null,"abstract":"The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework offers a structured approach to assess the certainty of evidence (CoE) in systematic reviews (SRs). The CoE for each outcome falls into one of the four categories: very low, low, moderate, or high. The judgment of CoE is based on five downgrading factors (including the risk of bias, indirectness, inconsistency, imprecision, and publication bias) and three upgrading factors (including large effect size, dose-response relationship, and opposing plausible residual bias and confounding). To improve the transparency of SRs, authors should indicate how they grade the CoE for each outcome and provide a rationale for downgrading or upgrading the CoE.","PeriodicalId":11107,"journal":{"name":"Dermatologica Sinica","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75818825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.4103/ds.v41-3-editorial
Shang-Hung Lin
The prolonged use of masks has been reported to cause adverse skin reactions in both health-care workers (HCWs) and the public. In this issue of Dermatol Sinica, Ku et al. conducted a narrative review to identify different adverse skin reactions and associated risk factors in HCW and the public with prolonged use of masks during the COVID-19 pandemic.[1] They reported that retroauricular dermatitis, cheilitis, rosacea, acne vulgaris, nasal bridge damage, itch, allergic contact dermatitis, and irritant contact dermatitis are common mask-related adverse skin reactions. In addition, the long duration of wearing masks, preexisting skin diseases, and being HCWs are highlighted as definite risk factors. This review summarized the mask-related dermatoses and the associated risk factors. Therefore, it helps HCWs and the public adopt appropriate preventative measures based on their individualized circumstances. Vitiligo is a chronic autoimmune depigmenting skin disorder resulting from the selective destruction of melanocytes. The pathogenesis of vitiligo is complex and the therapeutic choice for vitiligo was limited in the past. The wood’s light, dermoscopy, and clinical photography were traditionally used to diagnose vitiligo. Interestingly, several potential biomarkers and advanced noninvasive skin imaging such as reflectance confocal microscopy and optical coherence tomography have recently assisted in evaluating vitiligo disease activity and severity. The clinical management of vitiligo is aimed at halting disease progression and facilitating repigmentation. In this issue of Dermatol Sinica, Shen et al. update the pathogenesis of vitiligo, discuss emerging biomarkers for the assessment of vitiligo disease activity and severity, and summarize prospective targeted therapies in treating vitiligo.[2] Various scientific and technological breakthroughs have been achieved in the field of medicine, especially in the field of dermatology, improving the accuracy of disease diagnosis and treatment to a new stage, in which the application of Artificial Intelligence (AI) has played an indispensable role. However, a study in 2020 found that while 85% of dermatologists were aware that AI is an emerging technology conducive to the development of dermatology, only 24% had a better understanding of the field.[3] In this issue of Dermatol Sinica, Ye and Chen review the recent new development of AI in dermatology, to promote dermatologists in the better understanding and mastering of it.[4] In this issue of Dermatol Sinica, Song et al. reported that hypertrophic scar patients owned elevated HOX transcript antisense intergenic RNA (HOTAIR) and decreased miR-30a-5p.[5] HOTAIR knockdown can inhibit the proliferation, migration, and collagen synthesis of scar fibroblasts by negatively regulating the expression of miR-30a-5p. Ye et al. reported that dupilumab showed good efficacy and safety in patients with photodermatoses through light-induced type 2 inflammatory response.[6
{"title":"How to prevent mask-related adverse skin reactions","authors":"Shang-Hung Lin","doi":"10.4103/ds.v41-3-editorial","DOIUrl":"https://doi.org/10.4103/ds.v41-3-editorial","url":null,"abstract":"The prolonged use of masks has been reported to cause adverse skin reactions in both health-care workers (HCWs) and the public. In this issue of Dermatol Sinica, Ku et al. conducted a narrative review to identify different adverse skin reactions and associated risk factors in HCW and the public with prolonged use of masks during the COVID-19 pandemic.[1] They reported that retroauricular dermatitis, cheilitis, rosacea, acne vulgaris, nasal bridge damage, itch, allergic contact dermatitis, and irritant contact dermatitis are common mask-related adverse skin reactions. In addition, the long duration of wearing masks, preexisting skin diseases, and being HCWs are highlighted as definite risk factors. This review summarized the mask-related dermatoses and the associated risk factors. Therefore, it helps HCWs and the public adopt appropriate preventative measures based on their individualized circumstances. Vitiligo is a chronic autoimmune depigmenting skin disorder resulting from the selective destruction of melanocytes. The pathogenesis of vitiligo is complex and the therapeutic choice for vitiligo was limited in the past. The wood’s light, dermoscopy, and clinical photography were traditionally used to diagnose vitiligo. Interestingly, several potential biomarkers and advanced noninvasive skin imaging such as reflectance confocal microscopy and optical coherence tomography have recently assisted in evaluating vitiligo disease activity and severity. The clinical management of vitiligo is aimed at halting disease progression and facilitating repigmentation. In this issue of Dermatol Sinica, Shen et al. update the pathogenesis of vitiligo, discuss emerging biomarkers for the assessment of vitiligo disease activity and severity, and summarize prospective targeted therapies in treating vitiligo.[2] Various scientific and technological breakthroughs have been achieved in the field of medicine, especially in the field of dermatology, improving the accuracy of disease diagnosis and treatment to a new stage, in which the application of Artificial Intelligence (AI) has played an indispensable role. However, a study in 2020 found that while 85% of dermatologists were aware that AI is an emerging technology conducive to the development of dermatology, only 24% had a better understanding of the field.[3] In this issue of Dermatol Sinica, Ye and Chen review the recent new development of AI in dermatology, to promote dermatologists in the better understanding and mastering of it.[4] In this issue of Dermatol Sinica, Song et al. reported that hypertrophic scar patients owned elevated HOX transcript antisense intergenic RNA (HOTAIR) and decreased miR-30a-5p.[5] HOTAIR knockdown can inhibit the proliferation, migration, and collagen synthesis of scar fibroblasts by negatively regulating the expression of miR-30a-5p. Ye et al. reported that dupilumab showed good efficacy and safety in patients with photodermatoses through light-induced type 2 inflammatory response.[6","PeriodicalId":11107,"journal":{"name":"Dermatologica Sinica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135913337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.4103/ds.ds-d-23-00101
Yi-Hsien Chen, Jun Ma, Chien-Ping Chiang, Wei-Ming Wang, Chih-Tsung Hung
Dear Editor, A 64-year-old Taiwanese male, nonsmoker, with a history of hypertension and type 2 diabetes mellitus has been regularly taking metformin for glycemic control. The patient was previously diagnosed with biopsy-proven bullous pemphigoid after experiencing multiple itchy erythema and blisters all over the whole body for 3 months. He was treated with prednisolone 10 mg three times daily and azathioprine 25 mg daily. Lesions showed improvement during the first 2-week follow-up. However, while the prednisolone dose was tapered down to 10 mg daily, the disease flared up again. He presented at our hospital with multiple tense bullae and erosions on erythematous pruritic wheals over the neck, trunk, and limbs without mucosal involvement [Figure 1]. Laboratory tests revealed eosinophilia and elevated levels of immunoglobulin E (IgE). There were no positive findings for potential infectious risk factors such as hepatitis B virus, hepatitis C virus, and Cytomegalovirus, as well as tumor markers. The score of Bullous Pemphigoid Disease Area Index (BPDAI) is 69 and the Visual Analog Scale (VAS) of pruritus is 9.Figure 1: Multiple tense bullae and erosions on erythematous pruritic wheals over the (a) neck, anterior chest, and (b) bilateral thighs.Initially, we treated the patient with intravenous methylprednisolone 4 mg/day, doxycycline 100 mg twice daily, systemic antihistamines, and topical steroids. However, we observed hyperglycemia, with poor-controlled blood sugar levels increasing up to 480 mg/dL. After discussing the options with the patient, we prescribed oral baricitinib 4 mg/day. Subsequently, we initiated the tapering of the systemic steroid in 2 days. At 1-week follow-up, the erythema on the body has disappeared and no new blisters have formed. The pruritus has also subsided, leaving only the wounds from the ruptured blisters [Figure 2]. No flare-up was noted after 8-week follow-up without any adverse event, and the BPDAI and VAS of pruritus have decreased to 0 points.Figure 2: (a and b) After 2 weeks of baricitinib treatment, the lesions showed resolution with residual erythema and scarring.Baricitinib is a first-generation Janus kinase (JAK) inhibitor. It works by targeting JAK1 and JAK2 proteins, which play a key role in regulating the immune response and inflammatory pathways.[1] To date, baricitinib has been found to be effective in treating rheumatoid arthritis, alopecia areata, and atopic dermatitis. Although the mechanism of JAK inhibitors in treating blood pressure (BP) is not yet established, several studies have shown its efficacy. Xiao et al. reported successful treatment of concurrent BP and plaque psoriasis with baricitinib in an 83-year-old man, who showed significant improvement and complete remission without adverse effects.[2] Fan and Wang have reported that seven cases of recalcitrant BP were successfully treated with tofacitinib and maintained complete remission during 9 months of follow-up.[3] In the pathogenesis of
{"title":"Successful treatment of bullous pemphigoid with baricitinib: A case report","authors":"Yi-Hsien Chen, Jun Ma, Chien-Ping Chiang, Wei-Ming Wang, Chih-Tsung Hung","doi":"10.4103/ds.ds-d-23-00101","DOIUrl":"https://doi.org/10.4103/ds.ds-d-23-00101","url":null,"abstract":"Dear Editor, A 64-year-old Taiwanese male, nonsmoker, with a history of hypertension and type 2 diabetes mellitus has been regularly taking metformin for glycemic control. The patient was previously diagnosed with biopsy-proven bullous pemphigoid after experiencing multiple itchy erythema and blisters all over the whole body for 3 months. He was treated with prednisolone 10 mg three times daily and azathioprine 25 mg daily. Lesions showed improvement during the first 2-week follow-up. However, while the prednisolone dose was tapered down to 10 mg daily, the disease flared up again. He presented at our hospital with multiple tense bullae and erosions on erythematous pruritic wheals over the neck, trunk, and limbs without mucosal involvement [Figure 1]. Laboratory tests revealed eosinophilia and elevated levels of immunoglobulin E (IgE). There were no positive findings for potential infectious risk factors such as hepatitis B virus, hepatitis C virus, and Cytomegalovirus, as well as tumor markers. The score of Bullous Pemphigoid Disease Area Index (BPDAI) is 69 and the Visual Analog Scale (VAS) of pruritus is 9.Figure 1: Multiple tense bullae and erosions on erythematous pruritic wheals over the (a) neck, anterior chest, and (b) bilateral thighs.Initially, we treated the patient with intravenous methylprednisolone 4 mg/day, doxycycline 100 mg twice daily, systemic antihistamines, and topical steroids. However, we observed hyperglycemia, with poor-controlled blood sugar levels increasing up to 480 mg/dL. After discussing the options with the patient, we prescribed oral baricitinib 4 mg/day. Subsequently, we initiated the tapering of the systemic steroid in 2 days. At 1-week follow-up, the erythema on the body has disappeared and no new blisters have formed. The pruritus has also subsided, leaving only the wounds from the ruptured blisters [Figure 2]. No flare-up was noted after 8-week follow-up without any adverse event, and the BPDAI and VAS of pruritus have decreased to 0 points.Figure 2: (a and b) After 2 weeks of baricitinib treatment, the lesions showed resolution with residual erythema and scarring.Baricitinib is a first-generation Janus kinase (JAK) inhibitor. It works by targeting JAK1 and JAK2 proteins, which play a key role in regulating the immune response and inflammatory pathways.[1] To date, baricitinib has been found to be effective in treating rheumatoid arthritis, alopecia areata, and atopic dermatitis. Although the mechanism of JAK inhibitors in treating blood pressure (BP) is not yet established, several studies have shown its efficacy. Xiao et al. reported successful treatment of concurrent BP and plaque psoriasis with baricitinib in an 83-year-old man, who showed significant improvement and complete remission without adverse effects.[2] Fan and Wang have reported that seven cases of recalcitrant BP were successfully treated with tofacitinib and maintained complete remission during 9 months of follow-up.[3] In the pathogenesis of","PeriodicalId":11107,"journal":{"name":"Dermatologica Sinica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135913338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.4103/ds.ds-d-23-00100
Ching-Chi Chi, Jin-Ling Ku, Min-Hao Sun, Yi-Chang Yen
Wearing facial masks is a commonly used personal protection measure during the COVID-19 pandemic. However, prolonged use of masks has caused adverse skin reactions in both health-care workers (HCWs) and the public. In this study, we conducted a narrative review of mask-related adverse skin reactions and risk factors. Common mask-related adverse skin reactions include retroauricular dermatitis, cheilitis, rosacea, acne vulgaris, nasal bridge damage, itch, allergic contact dermatitis, and irritant contact dermatitis. Urticaria, facial pigmentation, and maceration were also reported as mask-related adverse skin reactions while the association was rarely reported. Long duration of wearing masks, preexisting skin diseases, and being HCWs are highlighted as definite risk factors. Skin conditions for example oily, dry, and sensitive skin lead to an increased risk of mask-related adverse skin reactions. In conclusion, this review provides a summary of mask-related dermatoses and their prevalence and risk factors. This article can inform the HCWs and the public to better identify mask-related adverse skin reactions and risk factors. Thus, they may adopt appropriate preventative measures based on their individualized circumstances.
{"title":"Mask-related adverse skin reactions and risk factors: A literature review","authors":"Ching-Chi Chi, Jin-Ling Ku, Min-Hao Sun, Yi-Chang Yen","doi":"10.4103/ds.ds-d-23-00100","DOIUrl":"https://doi.org/10.4103/ds.ds-d-23-00100","url":null,"abstract":"Wearing facial masks is a commonly used personal protection measure during the COVID-19 pandemic. However, prolonged use of masks has caused adverse skin reactions in both health-care workers (HCWs) and the public. In this study, we conducted a narrative review of mask-related adverse skin reactions and risk factors. Common mask-related adverse skin reactions include retroauricular dermatitis, cheilitis, rosacea, acne vulgaris, nasal bridge damage, itch, allergic contact dermatitis, and irritant contact dermatitis. Urticaria, facial pigmentation, and maceration were also reported as mask-related adverse skin reactions while the association was rarely reported. Long duration of wearing masks, preexisting skin diseases, and being HCWs are highlighted as definite risk factors. Skin conditions for example oily, dry, and sensitive skin lead to an increased risk of mask-related adverse skin reactions. In conclusion, this review provides a summary of mask-related dermatoses and their prevalence and risk factors. This article can inform the HCWs and the public to better identify mask-related adverse skin reactions and risk factors. Thus, they may adopt appropriate preventative measures based on their individualized circumstances.","PeriodicalId":11107,"journal":{"name":"Dermatologica Sinica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135913346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Acrocyanosis and retiform purpura as the first manifestation of catastrophic antiphospholipid syndrome in a child: A case report","authors":"CHIH-KAI Wong, Li-Ching Fang, Wei Hung, Yu-Hung Wu","doi":"10.4103/ds.ds-d-22-00086","DOIUrl":"https://doi.org/10.4103/ds.ds-d-22-00086","url":null,"abstract":"","PeriodicalId":11107,"journal":{"name":"Dermatologica Sinica","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87213796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.4103/ds.ds-d-23-00093
Yoshio Kawakami, Toshiyuki Yamamoto
1Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 2Department of Dermatology, Fukushima Medical University, Fukushima, Japan Address for correspondence: Dr. Yoshio Kawakami, Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama 700-8558, Japan. E-mail: [email protected] Received May 15, 2023 Received in revised form July 17, 2023 Accepted August 07, 2023
{"title":"Coexistence of scleredema adultorum of Buschke and psoriatic arthritis: A case report","authors":"Yoshio Kawakami, Toshiyuki Yamamoto","doi":"10.4103/ds.ds-d-23-00093","DOIUrl":"https://doi.org/10.4103/ds.ds-d-23-00093","url":null,"abstract":"1Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 2Department of Dermatology, Fukushima Medical University, Fukushima, Japan Address for correspondence: Dr. Yoshio Kawakami, Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama 700-8558, Japan. E-mail: [email protected] Received May 15, 2023 Received in revised form July 17, 2023 Accepted August 07, 2023","PeriodicalId":11107,"journal":{"name":"Dermatologica Sinica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135952812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.4103/ds.ds-d-22-00134
M. Saber, G. Faghihi, Seyed-Amirmohammad Seyedghafouri, S. Hosseini
Background: Information on the cause of death is critical in guiding decisions on health infrastructure. However, there is a relative paucity of mortality data in patients with dermatologic diseases. Objectives: We aim to assess the overall mortality from dermatological disorders in a third-level university hospital which serves as a dermatology referral center. Methods: A retrospective medical note review of patients with dermatologic diseases who died during an 11-year period (from March 2008 to February 2020) was undertaken. Results: There were 63 death cases out of 2810 admissions for patients with dermatologic diseases (crude mortality 2.24%). The average age was 61.8 years and the male-to-female ratio was 2.3. Cutaneous malignancies (53.96%) were the primary causes of death, followed by drug reactions (23.8%). Among skin cancers, squamous cell carcinoma (SCC; 47.05%) and melanoma (35.29%) were the leading causes of death. Toxic epidermal necrolysis (53.33%) was the leading cause of death among drug reactions. Sepsis (30.74%) was the most common immediate cause of mortality in this series. A large fraction of patients (73%) had significant underlying comorbidities. Conclusion: The principal cause of mortality was cutaneous malignancies (mainly SCC and melanoma) followed by drug reactions. Sepsis was the most common immediate cause of death.
{"title":"Mortality and cause of death in patients with dermatologic diseases: An 11-year record-based observational study","authors":"M. Saber, G. Faghihi, Seyed-Amirmohammad Seyedghafouri, S. Hosseini","doi":"10.4103/ds.ds-d-22-00134","DOIUrl":"https://doi.org/10.4103/ds.ds-d-22-00134","url":null,"abstract":"Background: Information on the cause of death is critical in guiding decisions on health infrastructure. However, there is a relative paucity of mortality data in patients with dermatologic diseases. Objectives: We aim to assess the overall mortality from dermatological disorders in a third-level university hospital which serves as a dermatology referral center. Methods: A retrospective medical note review of patients with dermatologic diseases who died during an 11-year period (from March 2008 to February 2020) was undertaken. Results: There were 63 death cases out of 2810 admissions for patients with dermatologic diseases (crude mortality 2.24%). The average age was 61.8 years and the male-to-female ratio was 2.3. Cutaneous malignancies (53.96%) were the primary causes of death, followed by drug reactions (23.8%). Among skin cancers, squamous cell carcinoma (SCC; 47.05%) and melanoma (35.29%) were the leading causes of death. Toxic epidermal necrolysis (53.33%) was the leading cause of death among drug reactions. Sepsis (30.74%) was the most common immediate cause of mortality in this series. A large fraction of patients (73%) had significant underlying comorbidities. Conclusion: The principal cause of mortality was cutaneous malignancies (mainly SCC and melanoma) followed by drug reactions. Sepsis was the most common immediate cause of death.","PeriodicalId":11107,"journal":{"name":"Dermatologica Sinica","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90828487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.4103/ds.ds-d-22-00121
T. Hsieh, Jau‐Shiuh Chen, T. Tsai
{"title":"Dyshidrotic bullous pemphigoid developing after Moderna mRNA-1273 vaccination","authors":"T. Hsieh, Jau‐Shiuh Chen, T. Tsai","doi":"10.4103/ds.ds-d-22-00121","DOIUrl":"https://doi.org/10.4103/ds.ds-d-22-00121","url":null,"abstract":"","PeriodicalId":11107,"journal":{"name":"Dermatologica Sinica","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77223413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.4103/ds.ds-d-22-00087
Jing Lim, L. Gew, Yin-Quan Tang
Background: Hyperpigmentation occurs when excess melanin accumulates in the skin and causes the skin to become darker in color. Pursuing attractive appearance and colorism have promoted the development of the skin whitening market globally. The proteins targeted in this research are tyrosinase-related protein 1, cyclic adenosine monophosphate response element-binding protein, receptor tyrosine kinase, and endothelin receptor type B. Objectives: This study aims to identify the potential of coumarin derivatives as novel effective, safe, and natural antimelanogenesis agents for whitening purposes or therapeutical intention to treat hyperpigmentation disorders. Methods: Four three-dimensional structures of the targeted proteins and 94 ligands were obtained from Protein Data Bank and PubChem, respectively. The ligands were docked against modified targeted proteins to examine the binding affinity and protein-ligand interactions using PyRx and BIOVIA Discovery Studio. The top 13 derivatives were selected for further analysis on the pharmacokinetic properties through SwissADME and pkCSM web servers. A total of eight compounds were further chosen to conduct multiple ligand simultaneous docking (MLSD). Results: Difenacoum is the most potential antimelanogenesis agent due to its strong inhibitory binding affinity in targeted protein models (5M8M, 4TQN, 5X93), but it does not exhibit favorable behavior pharmacokinetic properties. From the in silico pharmacokinetics screening, novobiocin sodium is the most potent derivative due to its relatively appropriate and safer properties. However, none of the ligand pairs investigated in MLSD possesses a synergistic effect on the binding affinity. Conclusion: Our findings identified colladin, farnesiferol C and novobiocin sodium may be promising natural resources for developing antimelanogenesis agents.
背景:当过多的黑色素在皮肤中积累并导致皮肤颜色变深时，就会发生色素沉着。追求漂亮的外表和色彩主义推动了全球美白市场的发展。本研究的目标蛋白是酪氨酸酶相关蛋白1、环腺苷单磷酸反应元件结合蛋白、酪氨酸激酶受体和内皮素受体b型。目的:本研究旨在确定香豆素衍生物作为新型有效、安全、天然的抗黑色素生成药物的潜力，用于美白目的或治疗色素沉着症。方法:分别从Protein Data Bank和PubChem中获取目标蛋白的4个三维结构和94个配体。利用PyRx和BIOVIA Discovery Studio将这些配体与修饰后的靶蛋白对接，检测它们的结合亲和力和蛋白质与配体的相互作用。通过SwissADME和pkCSM网络服务器对前13个衍生物的药代动力学特性进行进一步分析。共选择8个化合物进行多配体同时对接(MLSD)。结果:Difenacoum在靶向蛋白模型(5M8M, 4TQN, 5X93)中具有较强的抑制结合亲和力，是最有潜力的抗黑色素生成药物，但其没有表现出良好的行为药代动力学特性。从计算机药代动力学筛选来看，新生物素钠具有相对合适和安全的性质，是最有效的衍生物。然而，在MLSD研究的配体对中，没有一个对结合亲和力具有协同作用。结论:胶原蛋白、法尼铁酚C和新生物素钠可能是开发抗黑色素生成药物的有前途的天然资源。
{"title":"Biocomputational-mediated screening and molecular docking platforms for discovery of coumarin-derived antimelanogenesis agents","authors":"Jing Lim, L. Gew, Yin-Quan Tang","doi":"10.4103/ds.ds-d-22-00087","DOIUrl":"https://doi.org/10.4103/ds.ds-d-22-00087","url":null,"abstract":"Background: Hyperpigmentation occurs when excess melanin accumulates in the skin and causes the skin to become darker in color. Pursuing attractive appearance and colorism have promoted the development of the skin whitening market globally. The proteins targeted in this research are tyrosinase-related protein 1, cyclic adenosine monophosphate response element-binding protein, receptor tyrosine kinase, and endothelin receptor type B. Objectives: This study aims to identify the potential of coumarin derivatives as novel effective, safe, and natural antimelanogenesis agents for whitening purposes or therapeutical intention to treat hyperpigmentation disorders. Methods: Four three-dimensional structures of the targeted proteins and 94 ligands were obtained from Protein Data Bank and PubChem, respectively. The ligands were docked against modified targeted proteins to examine the binding affinity and protein-ligand interactions using PyRx and BIOVIA Discovery Studio. The top 13 derivatives were selected for further analysis on the pharmacokinetic properties through SwissADME and pkCSM web servers. A total of eight compounds were further chosen to conduct multiple ligand simultaneous docking (MLSD). Results: Difenacoum is the most potential antimelanogenesis agent due to its strong inhibitory binding affinity in targeted protein models (5M8M, 4TQN, 5X93), but it does not exhibit favorable behavior pharmacokinetic properties. From the in silico pharmacokinetics screening, novobiocin sodium is the most potent derivative due to its relatively appropriate and safer properties. However, none of the ligand pairs investigated in MLSD possesses a synergistic effect on the binding affinity. Conclusion: Our findings identified colladin, farnesiferol C and novobiocin sodium may be promising natural resources for developing antimelanogenesis agents.","PeriodicalId":11107,"journal":{"name":"Dermatologica Sinica","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83765073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：